2021
   Online, In the cloud

III-47 Jurij Aguiar Zdovc Model-based individualization of ustekinumab dosing in Crohn's disease

III-48 Orwa Albitar A Pharmacokinetic and Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Patients

III-49 Muhammad Waqar Ashraf A population pharmacokinetic model to quantify the role of in-vivo CYP2D6 activity in codeine metabolism for model informed precision dosing in ambulatory surgical patients.

III-50 Rebecca Baillie Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder

III-51 Amina Bensalem The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition

III-52 Rene Boosman The pemetrexed exposure-neutropenia relationship, paving the way to a safe administration in patients with an impaired renal function

III-53 Divakar Budda Prediction of CNS Target Engagement of Pain reliving Drugs in Health and Chronic Pain conditions

III-54 Laura Bukkems Population pharmacokinetics of Haemate P describing the interaction between factor VIII and Von Willebrand Factor levels in perioperative patients with von Willebrand Disease

III-55 Vera Bukkems A combined modelling approach to assess the efficacy and safety of doravirine in pregnant women

III-56 Elisa Calvier TMDD model to extrapolate free target reduction from competitor data in healthy volunteers to another drug in patients in order to select active dose range for phase II trials

III-57 Fernando Carreño Modelling of Dose-Response-Time Data Using a Population k-PD approach for Linerixibat, a Locally Acting Small Molecule with Minimal Systemic Absorption

III-58 Myriam Chartoire Development of mechanistic models for analysis and interpretation of cough challenge test data

III-59 Perrine Courlet Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control

III-60 Wilbert de Witte Continuous Time Markov Modelling in Systemic Lupus Erythematosus

III-61 Tayebeh Esmaeili Rivaroxaban Population Pharmacokinetics Modeling in Iranian Patients

III-62 Yu Fu A novel hemodynamic systems model to quantify pharmacodynamic effects on heart rate and contractility

III-63 Frédéric Gaspar A step towards Ticagrelor individualization based on pharmacokinetic approaches: which place for Physiologically-Based Modelling?

III-64 Mélanie Guhl Model-based analysis of PK equivalence: assessing the impact of model misspecification

III-65 Khalid Iqbal A PK-PD modelling and simulation-based evaluation of tedizolid dosing strategies for immunocompromised patients

III-67 Ranita Kirubakaran Matters close to the heart: adaptation of a tacrolimus model to inform tacrolimus therapy using the PRIOR approach

III-68 Christine Juliane Kleist Homoarginine population kinetics

III-69 Jane Knöchel Markov model demonstrates the importance of fibrosis distribution on clinical trial design in NAFLD/NASH

III-70 Niklas Kroemer Development and evaluation of D-optimal 2x2 checkerboard designs for identification of pharmacodynamic drug interactions

III-71 Julia Larsson A second-generation challenge model of TNFa turnover with LPS provocations and drug intervention

III-72 Li Li Model-Based Approach for assessing the Effect of Anti-Drug Antibodies on the PK of Therapeutic Proteins

III-73 Qiang Lu Semi-mechanistic Population Pharmacokinetic/Pharmacodynamic (Pop PK/PD) Modeling of Dupilumab on Nasal Congestion (NC) Score in Patients with Chronic Rhinosinusitis with Nasal Polyposis

III-74 Bastien Martin In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production

III-75 Saikumar Matcha Population Pharmacokinetics of Unbound Phenytoin after Administration of IV Fosphenytoin And Oral Phenytoin in Pediatric Patients.

III-76 Nicola Melillo Development and validation of a physiologically-based pharmacokinetic model of the imaging biomarker gadoxetate for prospective prediction of hepatic transporters drug-drug interactions

III-77 Yomna Nassar Quantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its metabolite 1-hydroxymidazolam

III-78 Karine Rodriguez-Fernandez Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics

III-79 Benjamin Schneider A Quantitative Systems Pharmacology Model for Bedside Optimization of ACE Inhibitor Dose Scheduling in Veterinary Cardiology

III-80 Daniel Seeler Towards understanding vascular (dys)regulation by linking endothelial cell morphology and blood vessel geometry

III-81 Sejung Hwang Effect of CYP2D6 genotype on pharmacokinetics and pharmacodynamics of carvedilol for the heart rate reduction in healthy subjects

III-82 Manna Semere Gebreyesus Population pharmacokinetics of esomeprazole in pregnant women with preterm preeclampsia

III-83 Monica Simeoni A Model Based Meta-Analysis for Bridging Treatment Doses of Rheumatoid Arthritis with Axial Spondyloarthritis

III-84 Leonid Stolbov A QSP approach to investigate the glucose-insulin dynamic following dapagliflozin treatment in patients with type 2 diabetes mellitus

III-85 David Ternant In-depth description of target-mediated pharmacokinetics of infliximab in inflammatory bowel disease patients

III-86 Wisse van Os Targeted temperature management reduces CYP2C19 metabolism: a population pharmacokinetic study using pantoprazole

III-87 Zhigang Wang Pharmacokinetic-Pharmacodynamic Model-Based Exploration of Alternative Ustekinumab Dosage Regimens for Patients with Crohn’s Disease

III-88 Liang Yang A quantitative pharmacology model for CB1 receptor mediated by Gi Gs protein competition

III-89 Miren Zamacona Population pharmacokinetic and exposure-response models for dapirolizumab pegol in patients with systemic lupus erythematosus

III-90 Chiara Zecchin mPBPK and PD modelling and simulation to predict drug and pharmacodynamic effect at site of action and guide the design of a phase 2A/B study